Integrating molecular docking and molecular dynamics simulation approaches for investigation of the affinity and interactions of Berberine with Class C β-Lactamase

Authors

DOI:

https://doi.org/10.60141/AJID/V.2.I.1.3

Keywords:

Molecular docking Molecular dynamics simulation, Berberine, Class C β-Lactamase

Abstract

Background: Antibiotic resistance is a significant health concern, as bacteria produce enzymes that inhibit antimicrobial drug activity, increasing disease generation. This study investigates the inhibitory effect of berberine on β-lactamase enzyme activity and antibiotic effectiveness.

Methods: Molecular docking was utilized to find the binding pose and binding affinity of a new inhibitory ligand with the AmpC enzyme using Autodock software version 4.2.2. MD simulations were performed in free form and complicated to understand the stability of the protein-ligand docked complex.

Results: The molecular docking result indicated the proper interaction between berberine and the AmpC β-lactamase enzyme with a suitable binding pose and binding energy of -6.55 kcal/mol. The MD simulation of systems verifies the docking result, which shows stable hydrogen bonds of berberine with AmpC and good equivalence between RMSD, RMSF, SASA, etc.

Conclusion:  This paper reveals that berberine, which is a natural ingredient with multiple medicinal characteristics, can be applied as a potential inhibitor of class C β-lactamase AmpC. Hence, the outcome of the calculations performed provides valuable data to design new inhibitors with therapeutic potential to control the β-lactamase activity.

Author Biographies

Allah Nawaz Safi, Ghalib University

Medical Sciences Research Center, Ghalib University, Kabul, Afghanistan.

Mohammad Sayed Behrad, Kabul University

Thoracic and Cardiovascular Surgery Department, Kabul University of Medical Science, Kabul, Afghanistan.

Sayed Hussain Mosawi, Ghalib University

Medical Sciences Research Center, Ghalib University, Kabul, Afghanistan.

Abdul Musawer Bayan, Ghalib University

Medical Sciences Research Center, Ghalib University, Kabul, Afghanistan.

References

Perera P, Ekanayake S, Ranaweera K. Antidiabetic compounds in Syzygium cumini decoction and ready to serve herbal drink. Evidence-Based Complementary and Alternative Medicine. 2017;2017.

Li X, Bai H, Yang Y, Yoon J, Wang S, Zhang X. Supramolecular antibacterial materials for combatting antibiotic resistance. Advanced Materials. 2019;31(5):1805092.

Xiang M-F, Jin C-T, Sun L-H, Zhang Z-H, Yao J-J, Li L-C. Efficacy and potential mechanisms of Chinese herbal compounds in coronavirus disease 2019: Advances of laboratory and clinical studies. Chinese medicine. 2021;16(1):1-13.

Nejatbakhsh F, Shirbeigi L, Rahimi R, Abolhassani H. Review of local herbal compounds found in the Iranian traditional medicine known to optimise male fertility. Andrologia. 2016;48(8):850-9.

Sindhu RK, Gupta R, Wadhera G, Kumar P. Modern herbal nanogels: formulation, delivery methods, and applications. Gels. 2022;8(2):97.

Brackman G, Coenye T. Quorum sensing inhibitors as anti-biofilm agents. Current pharmaceutical design. 2015;21(1):5-11.

Tan J, Wang J, Yang C, Zhu C, Guo G, Tang J, et al. Antimicrobial characteristics of Berberine against prosthetic joint infection-related Staphylococcus aureus of different multi-locus sequence types. BMC complementary and alternative medicine. 2019;19:1-10.

Liu D, Meng X, Wu D, Qiu Z, Luo H. A natural isoquinoline alkaloid with antitumor activity: studies of the biological activities of berberine. Frontiers in pharmacology. 2019;10:9.

Och A, Och M, Nowak R, Podgórska D, Podgórski R. Berberine, a herbal metabolite in the metabolic syndrome: The risk factors, course, and consequences of the disease. Molecules. 2022;27(4):1351.

Zhang S, Zhou L, Zhang M, Wang Y, Wang M, Du J, et al. Berberine maintains the neutrophil n1 phenotype to reverse cancer cell resistance to doxorubicin. Front Pharmacol. 2019.

Li H, Feng C, Fan C, Yang Y, Yang X, Lu H, et al. Intervention of oncostatin M-driven mucosal inflammation by berberine exerts therapeutic property in chronic ulcerative colitis. Cell death & disease. 2020;11(4):271.

Kwon M, Lim DY, Lee CH, Jeon J-H, Choi M-K, Song I-S. Enhanced intestinal absorption and pharmacokinetic modulation of berberine and its metabolites through the inhibition of P-glycoprotein and intestinal metabolism in rats using a berberine mixed micelle formulation. Pharmaceutics. 2020;12(9):882.

Sousa da Silva AW, Vranken WF. ACPYPE-Antechamber python parser interface. BMC research notes. 2012;5:1-8.

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic acids research. 2000;28(1):235-42.

Chen Y, Shoichet BK. Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nature chemical biology. 2009;5(5):358-64.

Mosawi SH, Mansoori H, Bayan AM, Fani N. Molecular docking and dynamics simulation of piperine as a potential inhibitor of class C beta-lactamase. Afghanistan Journal of Infectious Diseases. 2023;1(1):27-32.

Olsen L, Pettersson I, Hemmingsen L, Adolph H-W, Jørgensen FS. Docking and scoring of metallo-β-lactamases inhibitors. Journal of computer-aided molecular design. 2004;18:287-302.

Bayan AM, Mosawi SH, Fani N, Behrad MS, Mehrpoor AJ, Noori MY, et al. Integrating molecular docking and molecular dynamics simulation studies on the affinity and interactions of piperine with β-lactamase class A enzymes. Journal of Molecular Structure. 2023;1292:136151.

Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. Journal of computational chemistry. 2005;26(16):1701-18.

Downloads

Published

2024-01-10

How to Cite

Safi, A. N., Behrad, M. S., Mosawi, S. H., & Bayan, A. M. (2024). Integrating molecular docking and molecular dynamics simulation approaches for investigation of the affinity and interactions of Berberine with Class C β-Lactamase . Afghanistan Journal of Infectious Diseases, 2(1), 17–24. https://doi.org/10.60141/AJID/V.2.I.1.3